Amarin has confirmed that it plans to take its legal battle over Vascepa all the way to the US Supreme Court, as it seeks to overturn a ruling that has already allowed Hikma to launch its generic rival.
Amarin is prepared to take its US legal battle over Vascepa (icosapent ethyl) all the way to the country’s Supreme Court, after an appeals court refused to rehear a case involving Hikma and Dr Reddy’s that had seen six Vascepa patents ruled invalid, upholding an earlier district court decision.
Hikma has now launched its generic version. (Also see "Hikma Launches US Vascepa Rival As Amarin Appeal Denied" -...
In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.
The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
